News und Analysen
Charles River Laboratories Completes Acquisition of Vigene Biosciences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Vigene Biosciences, Inc. for $292.5 million in cash, subject
Valbiotis kündigt Durchführung klinischer Studie zur Wirkungsweise von TOTUM-63 durch INAF1 an der Universität Laval in Quebec City in Kooperation mit Nestlé Health Science an
Valbiotis (FR0013254851 - ALVAL, PEA/SME-fähig), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Vorbeugung und Bekämpfung von Stoffwechselkrankheiten
Simulations Plus Sets Date for Third Quarter Fiscal Year 2021 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its financial results for the third quarter of fiscal year 2021, the period ended May 31, 2021, after the close of the
Valbiotis Announces the Implementation of the TOTUM•63 Mode of Action Clinical Study by INAF1 at Laval University in Quebec City, in Partnership With Nestlé Health Science
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases
QUANTUM GENOMICS : QUORUM study : Results Announcement next August 27, 2021 at 10:30 am CEST
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and
LivaNova to Host Conference Call for Second Quarter 2021 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second quarter 2021 results on Wednesday, July 28, 2021 at 1 p.m
BOIRON : PROJECTED TIMETABLE OF THE NEXT PUBLICATIONS AND EVENTS 2022
The projected timetable of the next publications and events for the year 2022 is the following one:
Publications Date of publication (after market closing) Information meetings
Resolution Bioscience (a part of Agilent) Investigated Acquired Resistance to KRAS G12C Inhibition
Agilent Technologies Inc. (NYSE: A) today announced the publication of a study carried out in partnership with Resolution Bioscience (a part of Agilent) and Dana-Farber Cancer Institute. The paper
Initial Clinical Experience of FAP-2286 in Independent Named Patient Use Published in The Journal of Nuclear Medicine
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that Professor Dr. Richard P. Baum and Dr. Harshad R. Kulkarni, in conjunction with 3B Pharmaceuticals (Clovis’ licensing partner and
Waters to Help Accelerate Biologics Production Through Research Collaboration With Singapore’s Bioprocessing Technology Institute
Waters Corporation (NYSE:WAT) today announced an expansion of its joint work with the Bioprocessing Technology Institute (BTI), a research institute of Singapore's Agency for Science, Technology
First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that the first UK patient has been
Dexcom CGM Plays Starring Role at 81st Scientific Sessions of the American Diabetes Association
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today featured research and data presentations that will headline
Aurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application (MAA) for Voclosporin with the European Medicines Agency (EMA)
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the Company) announced today that the Company’s licensing partner, Otsuka Pharmaceutical Europe Ltd. (OPEL), filed an initial Marketing
Abbas Hussain Appointed as New Chief Executive Officer of Vifor Pharma
Regulatory News:
Abbas Hussain (56, British citizen) has a successful and international career of more than 30 years as an executive in the healthcare sector. From 2008 to 2017, Abbas Hussain
Abbas Hussain zum neuen Chief Executive Officer von Vifor Pharma ernannt
Regulatory News:
Abbas Hussain (56, britischer Staatsbürger) verfügt über eine mehr als 30-jährige erfolgreiche und internationale Karriere als Führungskraft im Gesundheitssektor. Von 2008 bis
Transgene: First Patient Enrolled in Expanded Phase II Clinical Trial of TG4001 + Avelumab Vs Avelumab Alone in Patients With HPV16-positive Anogenital Cancers
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that a first patient has
DexCom, Nick Jonas and Leading Diabetes Nonprofits Launch Initiative to Help Improve the Lives of People With Diabetes
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the launch of The Global Movement for Time in Range, an awareness
Waters Corporation Appoints Wei Jiang to Board of Directors
Waters Corporation (NYSE: WAT) today announced the appointment of Wei Jiang to its Board of Directors, effective July 14, 2021. Mr. Jiang currently serves as Executive Vice President and President
Macrophage Therapeutics, Inc. Wins Delaware Case Against Michael Goldberg for Breach of Fiduciary Duty
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Pfizer Declares Third-Quarter 2021 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a 39-cent third-quarter 2021 dividend on the company’s common stock, payable September 7, 2021, to holders of the Common
Vifor Pharma to revise DIAMOND study, readout expected in H2 2021
Regulatory News:
Vifor Pharma Group today announced that the phase-IIIb DIAMOND study has been amended with new and clinically relevant endpoints, including a new primary endpoint of efficacy in
Humana Expanding its Commitment to Improving Physical and Mental Health Across North Carolina
Leading health and well-being company Humana Inc. (NYSE: HUM) today announced it is expanding its commitment to the health and well-being of North Carolinians by more than doubling the number of
Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the first clinical site for the Phase 1/2 LuMIERE study of FAP-2286, its novel peptide-targeted radionuclide therapy and imaging agent
First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combination Study of Talazoparib and Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in TALAPRO-3, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial. The study will
Staff Care Survey: Locum Tenens Physicians Play Active Role in Treating Covid-19 Patients
Close to three quarters (71%) of locum tenens physicians and other advanced practice healthcare professionals working on a temporary basis have treated Covid-19 patients, according to a new survey